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Abstract
The Ctr1 family of integral membrane proteins is necessary for
high affinity copper uptake in eukaryotes. Ctr1 is also involved
in cellular accumulation of cisplatin, a platinum-based anticancer
drug. Although the physiological role of Ctr1 has been revealed,
the mechanism of action of Ctr1 remains to be elucidated. To
gain a better understanding of Ctr1-mediated copper and cisplatin transport, we have monitored molecular dynamics and transport activities of yeast Saccharomyces cerevisiae Ctr1 and its mutant
alleles. Co-expression of functional Ctr1 monomers fused with either cyan or yellow fluorescent protein resulted in fluorescence
resonance energy transfer (FRET), which is consistent with multimer assembly of Ctr1. Copper near the Km value of Ctr1 enhanced
FRET in a manner that correlated with cellular copper transport.
In vitro cross-linking of Ctr1 confirmed that copper-induced FRET
reflects conformational changes within pre-existing Ctr1 complexes. FRET assays in membrane-disrupted cells and protein extracts showed that intact cell structure is necessary for Ctr1 activity. Despite Ctr1-dependent cellular accumulation, cisplatin did
not change Ctr1 FRET nor did it attenuate copper-induced FRET.
A Ctr1 allele defective in copper transport enhanced cellular cisplatin accumulation. N-terminal methionine-rich motifs that are dispensable for copper transport play a critical role for cisplatin uptake. Taken together, our data reveal functional roles for structural
remodeling of the Ctr1 multimeric complex in copper transport
and suggest distinct mechanisms employed by Ctr1 for copper and
cisplatin transport.
Abbreviations: cisplatin, cis-diamminedichloroplatinum(II); BCS,
bathocuproine disulfonic acid; ECFP, enhanced cyan fluorescent
protein; EGS, ethyleneglycol bis(succinimidylsuccinate); EYFP, enhanced yellow fluorescent protein; FRET, fluorescence resonance
energy transfer; PIPES, 1,4-piperazinediethanesulfonic acid; MES, 4morpholineethanesulfonic acid; SC, synthetic complete; ICPMS, inductively coupled plasma mass spectrometry.
Introduction
Copper is a vital micronutrient required for the normal
growth and development of many organisms from bacteria
to humans (1). Copper mediates electron transfer reactions
by virtue of its ability to donate or accept electrons through
redox reactions (1). Thus, copper can serve as a cofactor for
enzymes involved in a variety of essential physiological pro-

cesses, including respiration, free radical detoxification, neurotransmission, iron metabolism, and signaling (1, 2). However, copper can readily catalyze reactions, which result in
the production of toxic hydroxyl radicals (3, 4). The essential
yet toxic nature of copper has been underscored by copperrelated disorders in humans and animals. Nutritional copper
deficiency leads to defects in growth and development (1, 2).
Menkes and Wilson diseases are characterized by symptoms
resulting from copper deficiency and excess accumulation,
respectively (5–7). Several multifactorial degenerative disorders, such as Alzheimer disease and prion diseases, are also
linked to imbalances in copper metabolism (8–10).
Delicate mechanisms for uptake, distribution, storage,
and excretion of copper are involved in homeostatic copper
metabolism. The baker’s yeast Saccharomyces cerevisiae has
been a useful model for the characterization of molecular
mechanisms of copper metabolism in eukaryotes, because
the structure and function for most of the molecular components involved in homeostatic metabolism of copper in yeast
are conserved in other eukaryotes, including humans (2, 11–
15). Extracellular copper exists in its oxidized form and is reduced by cell surface metalloreductases prior to transport
(16). Reduced copper appears to be the substrate of Ctr1-mediated copper uptake with a Km of 1~5 µM copper (17, 18, 31,
37). Ctr1 family members have been identified from a variety of eukaryotes such as yeast, plants, fruit fly, lizard, and
mammals (12). Characterization of yeast, mice, and human
cell lines where the Ctr1 gene is deleted or overexpressed
have demonstrated that Ctr1 is a necessary factor in high affinity copper uptake and supplies copper for all known copper-dependent physiological processes (17, 18, 31, 33, 38–
40). Once inside, chaperones such as Atx1 and CCS deliver
copper to the secretory compartment and to the copper-containing superoxide dismutase, respectively (19–22). Several
proteins, such as Cox17 and Sco1, are involved in copper insertion into cytochrome c oxidase (23–25). Copper sequestration is handled by metallothioneins, which chelate excess
copper to protect organisms from copper toxicity (26, 27).
Given that Ctr2 is a vacuolar copper exporter (28), the vacuole may also serve as a copper storage and detoxification organelle. The copper-dependent transcriptional regulation of
genes encoding components of copper acquisition and detoxification, including Ctr1 and metalloreductases, has been
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characterized in yeast (2, 12, 15, 26). In addition, copper can
also trigger the internalization and degradation of Ctr1 in
yeast and human cells (51, 52). These modes of regulation of
Ctr1 may play important roles in maintaining optimal levels of copper. However, given that contrasting results have
been reported as well (58, 59), the nature and physiological
significance of post-translational regulation of Ctr1 has not
been firmly established.
Recent studies have implicated a new role for Ctr1 in the
cellular accumulation of the chemotherapeutic drug cisplatin2 (cis-diamminedichloroplatinum(II)) and its analogues.
Deletion of the yeast and mouse Ctr1 results in increased cisplatin resistance and a decrease in cisplatin accumulation
(60). Human ovarian carcinoma cell lines overexpressing
Ctr1 exhibit an increase in cisplatin import (62). ATP7A and
ATP7B, two copper efflux transporters, are also involved in
cisplatin efflux (63–65). Although these observations suggest
that cisplatin uptake and extrusion employs copper transporters, the mechanism by which Ctr1 transports the chemically distinct copper and cisplatin, is poorly understood.
Ctr1 family members are integral membrane proteins
spanning three trans-membrane domains (12). Ctr1 proteins
are unique in their amino acid sequences and structural features (12, 15), however site-directed mutagenesis and truncation of Ctr1 have identified several residues that play roles in
multimer assembly and copper transport (36, 37, 55, 57). For
example, the methionine-rich motifs, which reside at the extracellular surface of Ctr1 family members appear to be involved in enhancing the efficiency of copper transport (36).
Three conserved methionine residues, one at the extracellular N terminus and two at the predicted second trans-membrane domain, have been proposed as copper binding residues during copper translocation (36) (Figure 1A). Several
lines of biochemical, genetic, and biophysical analyses indicate that Ctr1 multimerizes at the plasma membrane (31,33–
36,54). A recent projection structure of human Ctr1 determined using two-dimensional cryoelectron crystallography
further showed that human Ctr1 forms a compact trimer
with a novel channel-like architecture rather than the structural design of active transporters (53). This feature of Ctr1
assembly suggests that copper is translocated through the
pore formed at the center of the Ctr1 trimer complex. Alternatively, like other typical transporters Ctr1-mediated copper translocation may be coupled with structural remodeling
in the Ctr1 multimeric complex. Because Ctr1 family members do not carry a domain that is implicated in ATP utilization as a source of energy (2, 17, 12, 31), the electrochemical
gradient of free copper and/or other ions across the plasma
membrane may be the driving force for Ctr1-mediated copper transport (31).
To gain better insights into the mechanisms of action of
Ctr1, we monitored molecular events coupled with Ctr1
transport activities and measured cellular copper and cisplatin uptake in yeast S. cerevisiae. Co-expression of yeast Ctr1
monomers tagged with either cyan or yellow fluorescent protein at the cytoplasmic C terminus resulted in fluorescence
resonance energy transfer (FRET) in yeast cells. Quantification of copper-induced FRET changes between Ctr1 monomers in situ and cross-linking and Western blot analysis of
Ctr1 showed that copper induces conformational changes of
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the Ctr1 multimeric complex. Correlation of FRET changes in
Ctr1 with cellular copper uptake revealed an implication of
structural remodeling of Ctr1 in copper translocation, which
suggests transporter-like activity of Ctr1. Measurement of
cisplatin-induced Ctr1 FRET and cellular cisplatin accumulation by Ctr1 mutant alleles showed that the mechanism of
cisplatin uptake differs from the one employed during copper uptake.
Experimental Procedures
Strains, Media, and Growth Conditions—A BY4741 haploid
S. cerevisiae strain (MATa his3Δ1 leu2Δ0 met15Δ0 ura3Δ0), in
which Ctr1 gene is knocked out (ctr1::kanMX4) and Ctr3 gene
is not expressed (Open Biosystems) (43), was used for the experiments. Yeast cells were cultured with synthetic complete
(SC) media (2% dextrose, 0.2% amino acid mixture, and 0.67%
yeast nitrogen base) lacking specific markers for plasmid selection or YPD (2% dextrose, 2% Bacto-peptone, 1% yeast extract) media. Solid media were prepared with the supplementation of 1.5% agar. SUCFM medium (51) (0.67% yeast
nitrogen base minus copper (Bio 101), 0.08% amino acid mixture, 50 mM MES buffer, pH 6.1) was used for culturing cells
at low copper growth conditions. Yeast cell growth on nonfermentable carbon source media was tested using YPEG
media (2% Bacto-peptone, 1% yeast extract, 2% ethanol, 3%
glycerol, 1.5% agar). Yeast cells were cultured at 30 °C, if no
growth temperature is specified.
Plasmid Construction and Manipulation—Ctr1 and Ctr3 coding sequence was amplified from yeast genomic DNA by
PCR using gene-specific primer sets that are flanked by HindIII (5’-end) and XhoI (3’-end) sites. For the epitope tagging
at the C terminus of Ctr1, an NotI restriction enzyme site was
inserted in the reverse primer just before the stop codon. The
HindIII- and XhoI-digested PCR product was cloned into
the p415-TEF or p416-TEF yeast vector (44) for a constitutive
TEF gene promoter-mediated expression of Ctr1 and Ctr3.
ECFP and EYFP coding sequences without start and stop codons were PCR-amplified from pECFP-C1 and pEYFP plasmids (BD Biosciences-Clontech), respectively, with gene-specific primer sets flanked by NotI sites. The ECFP and EYFP
PCR products were inserted into the NotI site of Ctr1 cloned
in p416-TEF and p415-TEF vectors, respectively. A Ctr1 mutant allele carrying a site-directed mutation of the conserved
methionine (Met-127) to alanine (M1) and a mutant allele
with a deletion of all eight N terminus Met-rich motifs (Δ8)
(36) (Figure 1A) was inserted into the same vectors. ECFP or
EYFP was fused at the C-terminal tail of the Ctr1 mutant alleles. All constructs were confirmed by sequencing. Common
molecular biology techniques, including plasmid amplification using Escherichia coli, and purification, followed previously established methods (45). Plasmid transformation into
yeast was performed using the lithium acetate method (46).
Cells transformed with the p415-TEF and p416-TEF vectors
were selected and maintained using SC media lacking leucine and uracil.
Functional Assays of Ctr1 Fused with ECFP and EYFP—The
function of wild-type Ctr1 and Ctr1 fused with either ECFP
or EYFP was determined by complementation studies in the
BY4741 yeast strain carrying a Ctr1 deletion (ctr1Δ). Briefly,
BY4741 ctr1Δ cells expressing empty vector, wild-type Ctr1,
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or Ctr1 fused with ECFP and EYFP were grown to mid-log
phase (A600 = 1.0) in SC-selective media. Cells (~5 µl) were
spotted on YPEG media containing non-fermentable carbon
sources where BY4741 ctr1Δ cells are not able to grow due
to a defect in copper-dependent cytochrome c oxidase activities. Growth of BY4741 ctr1Δ cells transformed with vectors
expressing Ctr1 or ECFP- or EYFP-fused Ctr1 was compared.
Fluorescence Microscopy—BY4741 ctr1Δ cells expressing
wild-type or ECFP-tagged and/or EYFP-tagged Ctr1 were
grown in SC media lacking leucine and uracil to mid-log
phase. Cells were visualized using a confocal microscope
(Olympus FV500) to localize Ctr1-ECFP and Ctr1-EYFP and
determine the FRET between Ctr1 monomers. Cells were excited at 433 nm and 500 nm to observe ECFP and EYFP, respectively. Emission signals of ECFP and EYFP were detected at 475 nm and 525 nm, respectively. Images were
processed using Adobe Photoshop 8.0.
Quantification of FRET—A scanning fluorometer was used
to quantify FRET from yeast cells (BY4741 ctr1Δ) co-expressing functional Ctr1 tagged with either EYFP or ECFP at the
C terminus. The method for measuring FRET efficiency in
yeast cells suspended in buffer using a scanning fluorometry
has been previously described (47). Briefly, yeast cells cultured to mid-log phase in selective media were washed twice
using PIPES buffer (50 mM, pH 6.0), and re-suspended in the
same buffer to A600 1.0 (~107 cells/ml). Fluorescent emission
spectra by the excitation of ECFP or EYFP were obtained using a scanning fluorometer (PerkinElmer Life Sciences LS50).
Cells were excited at 433 nm (ECFP excitation), and the emission was recorded from 460 nm to 580 nm. The following factors were considered to calculate the FRET efficiency in cells
expressing both Ctr1-ECFP and Ctr1-EYFP. First, the emission spectrum from cells expressing untagged Ctr1 was subtracted to eliminate signal coming from auto fluorescence.
Second, the emission spectrum of cells expressing Ctr1-ECFP
and Ctr1 upon excitation of ECFP at 433 nm was obtained.
This spectrum was subtracted to eliminate emission resulting from excitation of ECFP. Third, the emission spectrum
upon excitation of EYFP at 433 nm of cells expressing Ctr1EYFP with untagged Ctr1 was subtracted, which eliminates
EYFP emission resulting from direct excitation at 433 nm.
The spectrum obtained after completing these three steps is
the EYFP emission resulting from FRET. FRET efficiency was
calculated by dividing the EYFP emission peak area resulting from FRET by the peak area of the EYFP emission resulting from direct excitation of EYFP at 500 nm. Excel and Igor
Pro (version 5.0) programs were used for data processing
and statistical analysis.
Metal-induced FRET—To measure copper-induced changes
in FRET, copper (CuCl2, 2.5–25 µM) was added to PIPES buffer (50 mM, pH 6.0) containing yeast cells. Cells were gently
mixed with copper at room temperature for 0–45 s and were
scanned with a fluorometer for 75 s (total incubation time,
75–120 s). To determine metal specificities and cisplatin effect
on Ctr1 FRET, we applied several metal ions, including silver
(AgNO3), cobalt (CoSO4), zinc (ZnCl2), and cadmium (CdCl2)
purchased from Sigma, and cisplatin (American Pharmaceutical Partners Inc. and Sigma). Temperature dependence in
copper-induced FRET was measured from cells preincubated
at 0, 10, 25, and 30 °C for 15 min.
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In Vitro FRET Assays—BY4741 ctr1Δ cells transformed
with Ctr1-ECFP and/or Ctr1-EYFP expression plasmids
were cultured in selective media to mid-log phase. Cells
were washed with ice-cold water and suspended in lysis buffer (phosphate-buffered saline, pH 7.5) with protease inhibitor mixture (Complete Mini, Roche Applied Science). Cells
were vortexed with acid-washed glass beads at full speed six
times for 2 min and centrifuged at 1000 × g for 3 min. The supernatant was considered as a broken-cell fraction. To solubilize proteins, the samples were incubated with Triton X-100
(1% final concentration) for 30 min on ice, and centrifuged at
16,000 × g for 15 min. The supernatant containing total protein extract was collected. Plasma membrane-disrupted cells,
and total protein extracts were suspended in PIPES buffer
(50 mM, pH 6.0) at the concentration of 60 µg/ml. FRET efficiency in the samples was measured with or without copper
supplementation by scanning fluorometry using the same
method as described above.
Western Blot Analysis—Protein extracts were denatured
in SDS sample buffer at 95 °C for 5 min, resolved by SDSPAGE, and transferred to a nitrocellulose membrane. Ctr1ECFP was detected by chemiluminescence using anti-GFP
antibodies (1:2,000) that detects not only GFP but also ECFP
and EYFP, followed by horseradish peroxidase-conjugated
anti-rabbit IgG antibodies (1:8,000, Santa Cruz Biotechnology, Santa Cruz, CA). Phosphoglycerate kinase was detected
as loading control by chemiluminescence using anti-phosphoglycerate kinase antibodies (1:4,000, Molecular Probes)
followed by horseradish peroxidase-conjugated anti-mouse
IgG antibodies (1:10,000, Amersham Biosciences).
Temperature-dependent 64Cu Uptake Assays—Cells were cultured to mid-log phase in selective media, washed twice using
PIPES buffer (50 mM, pH 6.0), and re-suspended in the same
buffer to A600 1.0 (~107 cells/ml). Cells were preincubated at
0, 10, 25, and 30 °C for 15 min. Radioactive 64Cu (specific activity of 15–30 mCi/µg CuCl2, Mallinckrodt Institute of Radiology at Washington University, St. Louis) was added to 1 ml
of cells to a final concentration of 15 µM, and cells were incubated for 105 s. Samples were quenched with ice-cold phosphate-buffered saline containing 10 mM EDTA, filtered, and
washed twice. 64Cu was quantified using a γ-counter (PerkinElmer Life Sciences 1470 Wizard). Values obtained from
empty vector control cells were subtracted from the values of
cells expressing Ctr1 and normalized to the cell number.
Measurement of Cellular Metal Levels—Yeast cells were cultured until mid-log phase, spun down, and resuspended in
50 mM PIPES buffer (pH 6.0). Cells were cultured with copper or cisplatin, washed two times in phosphate-buffered
saline containing 10 mM EDTA and 1 mM diethydithiocarbamate. Cell pellets were dissolved in 70% nitric acid and
subsequently diluted to 10% nitric acid. Total cellular metal
levels were measured by inductively coupled plasma mass
spectrometry (ICPMS).
Cisplatin Toxicity Assay—Yeast cells cultured to mid-log
phase in selective media were washed twice using YPD media, and re-suspended in YPD to A600 1.0 (~107 cells/ml).
Cells were cultured at 30 °C for 2 h with or without supplementation of cisplatin (0.5 mM) in the media. Cells were diluted and plated on YPD media. Plates were incubated at 30
°C, and colonies were counted after 2 days.
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Figure 1. Formation of functional oligomeric
complexes by yeast Ctr1 monomers tagged
with either ECFP or EYFP. A, schematic depiction of yeast Ctr1 monomer fused with ECFP or
EYFP at the cytosolic C terminus. The N-terminal extracellular region contains eight Met-rich motifs. The conserved Met-127 at the N terminus and
two Met residues at the second transmembrane region are indicated (*). Three trans-membrane domains are shown as rectangles. B, co-expressed Ctr1
monomers, tagged with either ECFP or EYFP (Ctr1ECFP or Ctr1-EYFP), are functional. Ctr1 knock-out
(ctr1Δ) cells were co-transformed with two plasmids
for the constitutive expression of Ctr1 with or without fusion of ECFP or EYFP. Cells (5 µl of A600 = 0.1)
cultured in synthetic complete media (SC) selecting
for the two plasmids, were spotted on SC and nonfermentable (YPEG) growth media without (C) or
with copper deficiency (100 µM BCS copper chelator supplementation to the media (YPEG plus BCS))
or copper addition (100µM CuCl2 (YPEG plus Cu)).
Cells were grown at 30 °C for 3 days on YPEG media and for 1 day on SC media before photography.
C, Ctr1 monomers fused with either ECFP or EYFP
oligomerize. Cells were excited at 433 nm and 500
nm to visualize ECFP and EYFP, respectively. Emission signals of ECFP and EYFP were detected at 475
nm and 525 nm, respectively, using a confocal microscope. D, a model of the multimer assembly and
FRET between Ctr1 monomers fused with ECFP or
EYFP.

Results
Ctr1 Multimer Formation in Situ—Yeast Ctr1 tagged at the
C terminus with enhanced cyan or yellow fluorescent protein (Ctr1-ECFP or Ctr1-EYFP) (Figure 1A) was constitutively
expressed in ctr1Δ cells. The functionality of the tagged alleles was determined by complementation of the copper deficiency phenotype of yeast cells resulting from the defect of
endogenous Ctr1 (Figure 1B). Yeast cells lacking Ctr1 (ctr1Δ
plus vector) cannot grow on YPEG media containing nonfermentable carbon sources such as ethanol and glycerol due
to defects in the function of cytochrome c oxidase, a copperrequiring enzyme (Figure 1B) (17). Yeast cells co-expressing
untagged (Ctr1-wt) and ECFP or EYFP-tagged Ctr1 (Ctr1ECFP or Ctr1-EYFP) did not exhibit any visible difference in
growth on YPEG media and copper-deficient YPEG media
supplemented with 100 µM BCS, a copper chelator (YPEG
plus BCS) (Figure 1B). The growth defect of ctr1Δ yeast cells
was reversed on YPEG media supplemented with excess copper (100 µM CuCl2) (YPEG plus Cu) and SC media containing a fermentable carbon source (glucose) lacking uracil and
leucine (SC) for selection of the transformed plasmids. These
results demonstrate that Ctr1 fused with ECFP or EYFP is
fully functional.
We next examined Ctr1 multimer assembly in situ using a FRET approach. FRET relies on the distance-dependent (10–100 Å) non-radiative transfer of energy between donor and acceptor chromophores and is a powerful technique
for studying molecular interactions (41, 42). Aliquots of yeast
cells expressing combinations of untagged and chromophore-tagged Ctr1 (Ctr1/Ctr1, Ctr1-ECFP/Ctr1, Ctr1/Ctr1EYFP, and Ctr1-ECFP/Ctr1-EYFP) were mounted on a glass
slide and excited at 433 nm (ECFP excitation) and at 500 nm

(EYFP excitation) using a confocal microscope. Emission signals for ECFP and EYFP were detected at 475 nm and 525 nm,
respectively. ECFP and EYFP emission upon excitation with
the corresponding wavelength is specific to cells expressing
either ECFP or EYFP (Figure 1C). Yeast cells expressing both
Ctr1-ECFP and Ctr1-EYFP emit EYFP signal when ECFP is
excited (Figure 1C), suggesting Ctr1-ECFP and Ctr1-EYFP
are close enough for FRET to occur (Figure 1D). This is consistent with the formation of multimeric complexes of Ctr1 in
situ. This FRET signal is specific between Ctr1 monomers, because cells co-expressing Ctr1-ECFP with Ctr3 C-terminally
fused with EYFP (34) did not induce FRET (data not shown).
To confirm the FRET detected in microscopy and to efficiently quantify it, we measured the FRET signal using a
scanning fluorometer. Cells expressing non-tagged Ctr1 (Ctr1
plus Ctr1), ECFP-tagged Ctr1 (Ctr1-ECFP plus Ctr1), EYFPtagged Ctr1 (Ctr1 plus Ctr1-EYFP), and ECFP- and EYFPtagged Ctr1 (Ctr1-ECFP plus Ctr1-EYFP) were grown overnight in selective media to mid log phase and suspended
in PIPES buffer (50 mM, pH 6.0) to A600 1.0 (~107 cells/ml).
Cells were excited at 433 nm (ECFP excitation) and emission
was recorded from 460 to 580 nm (Figure 2A). An emission
peak for ECFP at 475 nm (single triangle) was observed from
cells expressing Ctr1-ECFP and Ctr1 (dotted line) and Ctr1ECFP and Ctr1-EYFP (dashed dot line). An emission peak for
EYFP (double triangle) at 525 nm upon excitation of ECFP was
observed from cells expressing Ctr1-ECFP and Ctr1-EYFP or
Ctr1 and Ctr1-EYFP (dashed line). FRET was calculated as described under “Experimental Procedures” and is represented
by the solid line (Figure 2A). FRET between Ctr1 is consistent
to the data published by another group (54) during preparation of this report. To better quantify how efficiently ECFP
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Figure 2. Determination of FRET between Ctr1-ECFP and Ctr1EYFP in vivo using a scanning fluorometer. A, yeast cells expressing Ctr1 with or without fusion of ECFP or EYFP were excited at 433 nm
(ECFP excitation), and the emission spectrum was recorded from 460 nm to
580 nm. ECFP (▼) and EYFP (▼▼) emission peaks are indicated. FRET data
were analyzed as described under “Experimental Procedures.” B, FRET experiments were performed on cells expressing Ctr1-ECFP and Ctr3-EYFP
(Ctr1-ECFP + Ctr3-EYFP). C, determination of FRET efficiency. Cells expressing Ctr1-ECFP and Ctr1-EYFP (Ctr1-ECFP + Ctr1-EYFP) were excited at 500
nm (EYFP excitation) and the emission signal was recorded from 510 nm to
630 nm (dotted line). FRET was plotted on the same graph (solid line), and
FRET efficiency was calculated by dividing the FRET peak area by the EYFP
peak area. D, non-tagged Ctr1 was overexpressed in cells expressing Ctr1ECFP and Ctr1-EYFP (Ctr1-ECFP + Ctr1-EYFP + Ctr1). The FRET efficiencies of
cells expressing Ctr1-ECFP and Ctr1-EYFP (black bar) and of cells expressing Ctr1-ECFP and Ctr1-EYFP along with non-tagged Ctr1 (gray bar) were
compared (* = p < 0.001, Student’s t test). A, B, and C represent the average and D represents the average and standard deviation of four independent experiments.

emission excites EYFP through FRET, we calculated the
FRET efficiency by dividing the peak area of the FRET emission by the peak area of the emission spectrum generated by
exciting cells expressing Ctr1-ECFP and Ctr1-EYFP at 500 nm
(EYFP excitation) (Figure 2C). The FRET efficiency between
Ctr1 monomers is 10.1 ± 0.3% (Figure 3D, black bar). To determine whether this FRET signal was specific to interactions
between Ctr1 monomers or whether it was due to nonspecific collisions between ECFP and EYFP at the plasma membrane, FRET was measured from cells co-expressing Ctr1ECFP and Ctr3-EYFP, another trans-membrane protein, or
cytosolic EYFP. No visible FRET signal was detected in cells
co-expressing ECFP-tagged Ctr1 with either EYFP-tagged
Ctr3 (Figure 2B) or EYFP (data not shown). To further determine whether non-tagged Ctr1 competes for oligomerization
with the tagged-Ctr1, we overexpressed non-tagged Ctr1
along with Ctr1-ECFP and Ctr1-EYFP. Indeed, non-tagged
Ctr1 significantly reduced FRET efficiency to 6.6 ± 0.5% (Figure 2D, gray bar). Taken together, these results demonstrate
that FRET between Ctr1 monomers can be efficiently quantified in live yeast cells using a scanning fluorometer and that
this signal is specific to Ctr1 monomer interactions in situ.
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Figure 3. Copper-induced changes in FRET efficiency between
Ctr1-ECFP and Ctr1-EYFP. A, time course of copper-induced FRET in
Ctr1. Cells were cultured to exponential growth phase, washed, and re-suspended in PIPES buffer (50 mM, pH 6.0) to A600 1.0. Copper (5 µM CuCl2)
was supplemented to the cell suspension, and FRET efficiency was calculated
at different time points after the addition of copper (75–120 s, 0–45 s incubation and 75 s scanning) as described under “Experimental Procedures.” B,
copper dose response of Ctr1 FRET changes with or without ascorbate, a
copper reductant. Copper (CuCl2, 0.5–25 µM) was supplemented to the cell
suspension for 30 s, and cells were scanned for 75 s. To reduce copper, CuCl2
was preincubated with ascorbate (100 mM) for 1 h at room temperature and
supplemented to cells suspended in PIPES buffer at the shown concentrations (0.1–25 µM). FRET efficiencies obtained with (closed circle) or without
(open circle) addition of ascorbate were compared. C, metal specificity of Ctr1
FRET. AgNO3 (Ag), CoSO4 (Co), CdCl2 (Cd), and ZnCl2 (Zn) were applied to
the cell suspension in the micromolar range, and cells were scanned with a
fluorometer after addition of the metals. FRET efficiencies were calculated
and compared. D, temperature dependence of Ctr1 FRET and 64Cu uptake.
Cells suspended in PIPES buffer were incubated at different temperatures (0,
10, 25, and 30 °C) for 15 min, prior to the addition of copper (15 µM at 105
s). Copper-dependent FRET and 64Cu uptake were measured. FRET efficiencies (black bars) and 64Cu levels (gray bars) were compared. Each data point
represents average and standard deviation of at least four independent experiments. *, p < 0.001, Student’s t test.

Copper Enhances FRET in Ctr1 Multimeric Complexes—To
determine if the FRET signal produced in Ctr1 multimeric
complexes is sensitive to copper, yeast cells co-expressing
Ctr1-ECFP and Ctr1-EYFP were excited in the absence and
presence of 5 µM copper. Because FRET efficiency correlates
with the distance between the donor and the acceptor chromophores, the change in FRET efficiency in these complexes
is indicative of the motion of Ctr1-ECFP and Ctr1-EYFP resulting in a change of the distance between ECFP and EYFP.
Indeed, FRET between Ctr1-ECFP and Ctr1-EYFP was enhanced after the addition of copper (Figure 3A). To determine time-dependent FRET response after copper exposure,
cells were prepared as previously described and excited at
different time points after the addition of 5 µM copper (75–
120 s, 0–45 s incubation at 25 °C and 75 s scanning). The copper-induced FRET efficiency gradually increased and peaked
close to 2 min before saturating (Figure 3A). Because the
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Figure 4. Effect of copper on the FRET between non-functional
Ctr1 monomers. A, FRET was determined from cells transformed with
two plasmids constitutively expressing non-functional M127A Ctr1 mutants
(M1) with or without ECFP and/or EYFP fusion at the C terminus. B, copperdependent FRET in the M127A mutant Ctr1. Copper (CuCl2, 2.5 ~25 µM)
was added to the yeast cells suspended in PIPES buffer for 30 s, and the cells
were scanned for 75 s using a scanning fluorometer. FRET efficiencies as a
function of copper concentrations were calculated as described under “Experimental Procedures” and compared. Each data point represents the average and standard deviation of four independent experiments. C, FRET was
measured without or with copper (15 µM CuCl2 for 30 s) supplementation
on cells expressing functional Ctr3 along with the non-functional M1 mutant tagged with either ECFP or EYFP. FRET efficiencies were calculated (gray
bars) and compared with the efficiencies of cells expressing only ECFP- and
EYFP-tagged M1 (black bars).
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scanning by the fluorometer requires 75 s, for short time
point experiments (1–75 s), cells were fixed in paraformaldehyde (4%) under light-protection to minimize bleaching of
ECFP and EYFP, and then FRET was measured. Copper-induced FRET within 75 s was not statistically significant (data
not shown). To measure the copper dose response of FRET,
cells were scanned 30 s after the addition of various copper
concentrations (2.5–25 µM). A copper-dependent FRET induction was observed in the range of the Km of Ctr1 for copper, and FRET was saturated at higher copper concentrations
(Figure 3B, open circle). Because reduced copper rather than
oxidized copper is believed to be a substrate for Ctr1 and
the reduction is carried on by cell surface metalloreductases
(16), we tested whether copper reduction is the limiting step
of copper-induced FRET. Addition of copper preincubated
with ascorbate (100 mM), a copper reductant, to the FRET assay buffer resulted in a dramatic increase in FRET efficiency
(Figure 3B, closed circle). We next measured FRET efficiency
changes by other metal ions, including silver, cadmium,
zinc, and cobalt, by adding micromolar ranges of these metals to the assay buffer. Among these metals only silver (15
µM), which shares similar chemical properties with reduced
copper (48), exhibited a significant effect on Ctr1 FRET (Figure 3C). These results further support the conclusion that
FRET in Ctr1 is a copper-specific response. Because Ctr1-mediated copper transport is sensitive to temperature (31), we
correlated copper-induced FRET with 64Cu uptake at different temperatures (Figure 3D). FRET efficiency and 64Cu uptake were measured in cells suspended in PIPES (50 mM, pH
6.0) and incubated with 15 µM 64Cu. The FRET efficiency was
enhanced in a saturable fashion as the incubation temperature increased (Figure 3D, black bars). 64Cu uptake under the
same experimental conditions correlated to FRET (Figure 3D,
gray bars). Consequently, copper-induced FRET in Ctr1 mirrored the characteristics of Ctr1-mediated copper uptake.
Defect in Copper-induced FRET in a Non-functional Ctr1
(M127A) Mutant—We next asked whether copper would
have the same effect on FRET from a non-functional Ctr1
mutant. A Ctr1 mutant possessing a conserved extracellular methionine (Met-127) to alanine mutation (M1) (36) was
fused with ECFP and/or EYFP. Two independent constructs
were co-transformed in Ctr1 knock-out yeast cells. Expression and localization of the M1 mutant alleles is indistinguishable from that of wild-type Ctr1, but they are non-functional in copper transport (data not shown). FRET between
the M1 mutants demonstrated that they form multimeric
complexes (Figure 4, A and B). However, no copper-induced
FRET was observed in the M1 multimer at copper concentrations up to 25 µM (Figure 4B). This further suggests that
copper-induced FRET in Ctr1 is coupled with copper transport. To test whether the copper transported into the cytoplasm by other pathways induces Ctr1 FRET, we expressed
Ctr3 along with the non-functional mutant M1 tagged with
either ECFP or EYFP. Ctr3 is a Ctr1 family member in yeast
that is functionally redundant to Ctr1, and our FRET assay
between Ctr1 and Ctr3 showed that they do not physically
interact in vivo (Figure 2B). Ctr3 co-expressed with M1 mutants enhanced intracellular copper accumulation as determined by growth assay on copper-requiring media (data not
shown). However, intracellular copper transported through
Ctr3 did not lead to copper-dependent FRET changes be-
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Figure 5. In vitro cross-linking of the Ctr1 oligomeric complex to ascertain copper-dependent Ctr1 conformational changes. Ctr1 knockout cells expressing Ctr1-ECFP and Ctr1-EYFP were cultured in synthetic
complete media with or without copper supplementation (5µM for 2 min).
Total protein extracts were incubated with a primary amine cross-linker EGS
at the shown concentrations and resolved by non-reducing SDS-PAGE. Ctr1
was detected by Western blot analysis with anti-GFP antibodies. Phosphoglycerate kinase (PGK) in the same samples was detected using anti-phosphoglycerate kinase antibodies as a control of specificity of Ctr1 cross-linking.
Bands corresponding to the monomer and trimer species of Ctr1-ECFP are
indicated with one and three black ovals, respectively.

tween the M1 mutants (Figure 4C), suggesting that copperinduced FRET in Ctr1 is coupled with the copper movement
through the Ctr1 channel. Interestingly, Ctr3 co-expression
reduced FRET in the M1 mutant multimers (Figure 4C), possibly because Ctr3 may sequester other cellular component(s)
that influence FRET in Ctr1.
Copper-induced FRET Changes in Ctr1 Occur as a Consequence of Conformational Changes in Pre-existing Ctr1 Complexes—We next examined copper-dependent Ctr1 structural
changes using an in vitro protein cross-linking approach. Total protein extracts were prepared from yeast cells expressing Ctr1-ECFP cultured in media with or without copper
(5 µM, 2 min) supplementation. The protein extracts were
cross-linked using ethyleneglycol bis(succinimidylsuccin
ate) (EGS), which is a primary amine cross-linker and separated on SDS-PAGE. Ctr1-ECFP was detected by Western
blot analysis using anti-GFP antibodies (Figure 5). Increasing EGS concentrations shifted all the monomeric species of
Ctr1 to the predicted homotrimer and higher oligomeric species suggesting that Ctr1 exists as a multimer in total protein
extracts. Because phosphoglycerate kinase in the samples is
detected as a monomeric species, the cross-linking is Ctr1
specific. Interestingly, cross-linking of Ctr1 to multimeric
species was much more efficient in protein extracts prepared
from copper-treated cells when compared with protein extracts from control cells (Figure 5, lane 2 versus lane 6). Ctr1
in cells cultured with copper-supplemented media likely carries a distinct conformation that is more favorable for EGS
cross-linking. Moreover, these data suggest that the copper-induced FRET (Figure 3) must represent conformational
changes, which occur in pre-existing multimer complexes
rather than new multimer formation, because all of the Ctr1
exists as trimer and higher complexes in both control and
copper-treated cells (Figure 5, lanes 4 and 8).
In Vitro FRET Assays Showed That Proper Location of Ctr1 Is
Necessary for Its Function—Copper uptake is not dependent
on cellular ATP levels (31), but it appears that extracellular
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Figure 6. In vitro FRET analyses. Yeast cells expressing Ctr1 with or without fusion of ECFP or EYFP were vortexed with glass beads to perturb the
membrane structure. Total proteins were extracted from the samples using
Triton X-100 (1% final concentration). The broken cells (Membrane plus Cytoplasm, black bars) and protein extracts (gray bars) were re-suspended in
PIPES buffer (60 µg/ml). Ctr1 FRET efficiency in the samples was measured
using a scanning fluorometer in the presence or absence of copper (15 µM
CuCl2 for 30 s). Each data point represents the average and standard deviation of four independent experiments.

K+ and acidic pH stimulate copper uptake (31, 50). Transmembrane ionic gradients are known to be an important factor for several transport mechanisms, such as co-transport
of proton and iron through DMT1 (DCT1 or Nramp2) divalent metal transporter (49). To examine the roles for transmembrane ionic gradient in Ctr1 activity, we measured Ctr1
FRET in membrane-disrupted cells and protein extracts from
cells expressing ECFP or EYFPfused Ctr1. The plasma membrane was perturbed by vortexing cells with glass beads as
described under “Experimental Procedures.” No live yeast
cells remained under these conditions as confirmed by a cell
growth assay on solid media (data not shown). Total protein extract was prepared by incubation of broken cells with
1% Triton X-100. The samples were suspended in PIPES buffer, and FRET was measured using a scanning fluorometer.
FRET in broken cells and protein extracts was similar to that
in intact cells (Figure 6), suggesting that Ctr1 maintains a
multimeric complex in these samples. However, copper did
not enhance FRET (Figure 6), suggesting no changes in the
conformation of the Ctr1 multimer complex. To account for
the possibility that copper reductases are not active under
these experimental conditions, FRET induced by copper preincubated with ascorbate was measured. However, reduced
copper again had no effect on Ctr1 FRET (data not shown).
These data suggest that Ctr1 location at intact cell membranes is necessary for acquiring a driving force for conformational changes.
Cisplatin Does Not Induce Ctr1 FRET or Compete with Copper for FRET—Genetic and biochemical studies in yeast and
mammalian cells have convincingly demonstrated that Ctr1
is a major factor for cellular accumulation of cisplatin (60–63,
66). However, it is still unclear whether Ctr1-mediated cisplatin accumulation employs the same mechanism used for copper uptake, particularly when considering the difference in
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Figure 7. Effect of cisplatin on the Ctr1 FRET and Ctr1-dependent
cellular cisplatin accumulation. A, cisplatin dose-response of Ctr1 FRET.
Yeast cells expressing Ctr1 with or without fusion of ECFP or EYFP were cultured to exponential growth phase, washed, and re-suspended in PIPES buffer (50 mM, pH 6.0) to A600 1.0. Cisplatin (25–100 µM) was supplemented to
the cell suspension for 30 s and cells were scanned for 75 s. FRET efficiency
was compared. B, time dependence of cisplatin-induced Ctr1 FRET. Cisplatin (50 µM) was supplemented to the cell suspension. Cells were scanned at
105 and 300 s after the addition of cisplatin (30 and 225 s incubation, respectively, and 75 s scanning). FRET efficiency was compared. C, cells treated with
cisplatin under the same conditions as FRET were collected and washed, and
cellular platinum levels were measured using ICPMS. D, effect of cisplatin on
copper-enhanced Ctr1 FRET. FRET efficiencies were measured in cells resuspended in PIPES buffer to A600 1.0 with or without copper (15 µM) and
cisplatin (100 µM). Data represent the average ± S.D. of four independent
measurements. Statistical significance between data were compared by Student’s t test as indicated.

structure and chemical properties between cisplatin and copper. Because copper enhanced Ctr1 FRET in a manner that
correlated with cellular copper uptake, we inquired whether
cisplatin would have the same effect. Yeast cells co-expressing Ctr1-ECFP and Ctr1-EYFP were excited in the absence
and presence of cisplatin. However, FRET between Ctr1ECFP and Ctr1-EYFP was not changed after the addition of
various concentrations of cisplatin (Figure 7A) even after 5
min of exposure (Figure 7B). To determine whether cells
were accumulating cisplatin, platinum levels in cells were
measured under the experimental condition used for FRET
analysis. Cells were suspended in PIPES (50 mM, pH 6.0) and
incubated either with 100 µM cisplatin for 105 s or 50 µM cisplatin for 300 s. Cell associated platinum was measured using ICPMS. Under both conditions cisplatin was at least one
and a half times higher in cells expressing Ctr1 (Figure 7C,
gray bars) when compared with control cells expressing an
empty vector (Figure 7C, black bars), which shows that Ctr1
enhances cellular cisplatin levels despite no FRET change being observed. To determine whether cisplatin could attenuate the effect of copper on Ctr1 FRET through competition,
we measured Ctr1 FRET in cells suspended in PIPES (50 mM,
pH 6.0) and incubated with 15 µM copper in the presence or
absence of 50 µM cisplatin (Figure 7D). Copper enhancement
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of Ctr1 FRET efficiency was not significantly changed in the
presence of excess cisplatin.
Cisplatin Accumulation and Toxicity in Cells Expressing Ctr1
Mutants—We next tested whether cisplatin could accumulate in cells expressing the Ctr1 (M127A) mutant (M1), which
is defective in copper uptake (36) and does not display copper-enhanced FRET (Figure 4B). ctr1Δ cells expressing either empty vector, Ctr1, or Ctr1(M127A) mutant (M1) were
grown to mid-log phase resuspended in PIPES (50 mM, pH
6.0) and incubated with 15 µM copper or 50 µM cisplatin for
300 s. Cell-associated copper and cisplatin were measured using ICPMS. As expected the non-functional mutant M1 failed
to accumulate copper (Figure 8A). However, accumulation of
platinum in cells expressing either Ctr1(M127A) or wild-type
Ctr1 was similar to each other (Figure 8B), suggesting that the
Ctr1 mutant defective in copper uptake is able to enhance cellular cisplatin levels. Because it was proposed that cisplatin induces multimer stabilization of human Ctr1 through N-terminal methionine-rich motifs (67), we tested whether yeast cells
expressing a Ctr1 allele with a deletion of all eight N terminus
Met-rich motifs (Δ8) could accumulate cisplatin. In contrast to
enhanced copper transport by the Δ8 mutant (Figure 8A), no
difference in cellular cisplatin accumulation was observed in
cells expressing Δ8 when compared with cells expressing an
empty vector (Figure 8B). We next correlated cellular cisplatin
accumulation with sensitivity to cisplatin. Because cells lacking Ctr1 or expressing the non-functional M1 allele are generally less healthy when compared with cells expressing a functional Ctr1, we co-expressed Ctr3 copper transporter in cells
expressing vector, wild-type Ctr1, M1, or Δ8. Ctr3 does not affect cisplatin uptake (60). Cells were cultured in YPD media
for 2 h with or without supplementation of 0.5 mM cisplatin,
and plated on YPD media (60). After 2 days cell survival was
measured as a percentage of colonies from cisplatin-treated
cultures compared with colonies from controls. Consistent to
the fact that Δ8 does not affect cellular cisplatin accumulation,
yeast cells expressing Δ8 showed resistance to cisplatin when
compared with cells expressing Ctr1 or M1 (Figure 8C). These
data suggest a critical role for the N-terminal Met-rich motifs,
but not for the conserved Met-127, in Ctr1-mediated accumulation and toxicity of cisplatin.
Discussion
Physiological roles of Ctr1 in both copper transport and
cellular cisplatin accumulation have been established. However the mechanisms of action employed by Ctr1 during
these processes remain poorly understood. Our data support
the conclusion that Ctr1-mediated copper transport is coupled with structural rearrangements of Ctr1 mutimeric complexes. This suggests that Ctr1 possesses transporter activity
rather than serving as a pore for copper translocation across
the plasma membrane, even though it was shown that Ctr1
forms a structure similar to an ion channel and the transmembrane pore is not structurally occluded (53). Moreover,
monitoring cisplatin-induced FRET and cellular cisplatin accumulation by mutant Ctr1 alleles revealed that the mechanism for Ctr1-mediated cisplatin transport is distinct from
that of copper.
Although yeast Ctr1 possesses a relatively long (~127
amino acids) C-terminal tail compared with other family
members (12), ECFP and EYFP independently fused at the
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end of the C terminus of Ctr1 are within a distance in which
FRET can occur. This suggests that yeast Ctr1 is composed
with at least two Ctr1 monomers in situ. Given that human
Ctr1 forms a homotrimer (53), yeast Ctr1 likely forms a trimeric complex as well. However, our in vitro cross-linking
and Western blot analysis of ECFP-fused Ctr1 interestingly
showed not only a predicted trimer but also higher molecular weight complexes. It is possible that yeast Ctr1 may form
a homo multimer complex higher than a trimer or associate
with other proteins to form a functional copper transporter.
Functional hetero and homo multimers have been observed
in many transporters and ion channels. For example, P2X
chloride channels and TRP channels are assembled by either
homo or hetero multimerization of monomeric isoforms (68,
69). It is interesting to note that Ctr4 and Ctr5 two distinct
Ctr1 homologues in Schizosaccharomyces pombe form a heteromultimeric complex, which is necessary for proper localization of each subunit to the plasma membrane and transporter
activity (35). However, FRET analysis between Ctr1 and Ctr3
suggests that these Ctr1 family members do not form heteromultimers. Given that humans, plants, and fruit flies as well
as yeast express more than one Ctr1 family proteins (12), the
possibility of heteromultimer formation between Ctr1 family
members in these species remains to be tested.
Quantification of FRET in a suspension of yeast cells using a scanning fluorometer is an efficient and powerful
method for determining protein-protein interactions in situ
and monitoring subtle and transient conformational changes
associated with protein activities. Extracellular copper specifically enhanced FRET between ECFP- and EYFP-tagged
Ctr1 monomers and intracellular copper transported by
other pathways does not induce Ctr1 FRET. Thus, copper
binding in the extracellular domain of Ctr1 must be transmitted through the transmembrane domains of Ctr1. Considering that FRET is proportional to the distance between the donor and acceptor (41, 42), enhanced FRET between ECFP and
EYFP is a clear indication of motion of the cytosolic C termini
leading to a shorter distance between the two fluorophores.
Several lines of evidence presented in this study strongly
suggest that copper-induced FRET is associated with Ctr1mediated copper transport. First, the changes in FRET in response to copper correlate with the characteristics of Ctr1mediated copper uptake. Second, the copper-induced FRET
does not occur in a non-functional Ctr1 complex. This observation suggests that, despite the fact that Ctr1 forms a channel-like architecture carrying an unoccluded pore at the symmetric subunit interface (53), Ctr1 behaves like a transporter
rather than a pore during copper transport. Although the homology in amino acid sequences of Ctr1 family members is
not significant (12), biochemical and genetic analyses of the
structure-function relations of yeast and human Ctr1 have
suggested that the mode of action is conserved among Ctr1
family members (36). The conformational changes observed
in yeast Ctr1 complexes likely occur in other Ctr1 family
members, including human Ctr1. Consistently, it has been
reported that the presence of copper during tryptic cleavage
of human Ctr1 results in protection of the cytoplasmic loop
between the predicted first and second transmembrane domains (37), which independently suggests copper-induced
conformational changes in a Ctr1 family member.
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Figure 8. Ctr1 mutant defective in copper uptake enhances cellular accumulation of cisplatin. A, BY4741 ctr1Δ cells transformed with either empty vector (V), wild-type Ctr1 (WT), M127A Ctr1 (M1), or Ctr1 lacking all N-terminal eight Met-rich motifs (Δ8) were cultured in selective media
to mid-log phase, resuspended in 50 mM PIPES (pH 6.0) and cultured with 15
µM copper at 30 °C for 5 min. Cells were collected and washed with PIPES
buffer containing EDTA (10 mM), and cell-associated copper levels were measured by ICPMS. Data represent the average ± S.D. of four independent measurements. B, cells prepared as in A, were cultured with 50 µM cisplatin at 30
°C for 5 min. Cells were collected and washed with PIPES buffer containing
cisplatin chelator diethydithiocarbamate (1 mM), and cell-associated platinum
levels were measured by ICPMS. C, cisplatin sensitivity conferred by Ctr1
wild-type and mutants. BY4741 ctr1Δ cells expressing Ctr3 transformed with
either empty vector (V), wild-type Ctr1 (WT), M127A Ctr1 (M1), or Ctr1
lacking all N-terminal eight Met-rich motifs (Δ8) expression construct. Cells
grown in the plasmid selection media were re-suspended in YPD media (A600
1.0) and were cultured at 30 °C for 2 h with or without 0.5 mM cisplatin
supplementation. Cells were diluted and plated on YPD solid media. After incubating the plates at 30 °C for 2 days, growing colonies were counted. Data
are expressed as percentages of colonies formed from cells exposed to cisplatin compared with colonies formed from control cells. Statistical significance
between data were compared by Student’s t test as indicated.
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Previous studies on Ctr1-mediated copper transport in a
mammalian cell line showed that proton and potassium levels in buffer or culture media affect Ctr1 activity (31), however the role of the transmembrane ionic gradient in Ctr1mediated copper transport remains to be elucidated. Ctr1 in
either membrane patches or protein extracts prepared using
a buffer containing 1% Triton X-100 exhibited FRET, suggesting that Ctr1 still maintains a multimer complex under these
conditions. However, copper did not induce FRET changes
in Ctr1. Copper-induced structural changes in Ctr1 appear
to require a specific environment maintained by live cells. A
Ctr1 functional assay using purified Ctr1 or heterologous expression systems and structural characterization of Ctr1 in vitro may not reflect activity and structure of Ctr1 as expressed
in its natural environment.
We propose that conformational changes in the Ctr1 multimeric complex play important roles in function and regulation of Ctr1. Copper binding to Ctr1 may initiate conformational changes that are transduced throughout the Ctr1
channel culminating with a motion of the C terminus tail
when copper is released into the cytoplasm. Structure-function analysis of Ctr1 showed that three Met residues conserved throughout the Ctr1 family of proteins are necessary
for Ctr1-mediated copper transport (36). These Met residues located at the extracellular N-terminal domain (~20
amino acids away from the first transmembrane domain)
and the second transmembrane domain have been proposed as copper-binding residues (36). The three conserved
methionines may serve as a selective filter for copper. Considering that Ctr1 forms a homotrimer, the external face of
Ctr1 carries at least nine Met residues. However, no apparent copper binding residues, such as Met, Cys, and His, are
conserved throughout the rest of the transmembrane region of Ctr1 family members. Thus, it is uncertain how copper moves from the periplasmic side to the cytoplasm and
whether it is coordinated when it traverses the channel. Conformational rearrangement of the Ctr1 transmembrane domain induced by copper binding at the cell surface may be
sufficient for removing the steric barrier(s) formed in the
transmembrane pore. High-resolution snapshot structures
of Ctr1 multimeric complexes in the copper-translocation cycle would further elucidate the dynamics of Ctr1 which we
have observed in living cells. When copper reaches the cytoplasmic end of the pore, the cytoplasmic domains may coordinate copper and may be involved in its subsequent relay to cytoplasmic carriers. A few predicted copper binding
residues, including at least one conserved cysteine residue,
are present in these domains (data not shown). Because it has
been shown that virtually no free copper exists in cells (70),
it is reasonable to predict that interactions between intracellular copper chaperones and Ctr1 may be involved in efficient copper transport without releasing copper to the cytoplasm. FRET between Ctr1 and copper chaperones would be
a useful approach for gaining further insights into molecular
mechanisms of copper uptake across the plasma membrane.
In addition, structural remodeling of Ctr1 may be implicated
in regulation of its activity and expression at the cell surface.
Copper-induced conformational changes in Ctr1 may expose
regulatory domains or lead to formation of new domains,
which attract other components of the copper uptake system. Because it was reported that Ctr1 in yeast and mamma-
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lian cells undergoes copper-induced endocytosis and degradation (51, 52), a specific conformation of Ctr1 resulting from
excess copper exposure may recruit the machinery involved
in the post-translational regulation of Ctr1.
An interesting dilemma about the structure and function
of Ctr1 implicates the role of this transporter in the uptake of
cisplatin, a widely used and effective cancer chemotherapy
agent. Treatment failure is often associated with increased resistance to this drug. Cisplatin resistance has been ascribed
to various mechanisms, including decreased accumulation,
increased efflux, enhanced cellular detoxification, and DNA
damage repair (71–73). Several previous reports suggest an
implication of copper metabolism pathways in the uptake,
chelation, and extrusion of cisplatin. Ctr1 is an important factor determining cellular cisplatin accumulation (60–62). Cisplatin can also induce expression of metallothionein, a chelator
of copper and other metal ions (56, 76). Enhanced expression
of copper efflux P-type ATPases has been observed in cisplatin-resistant cancer cells (63–65). However, the mechanistic
basis of the implication of copper metabolic pathways in cisplatin metabolism remains uncertain. Our data clearly show
that, despite Ctr1-dependent cellular accumulation, cisplatin
did not affect Ctr1 FRET. Moreover, a Ctr1 mutant defective
in copper uptake enhances cisplatin accumulation, whereas
a copper transport-active Ctr1 mutant lacking all eight N terminus Met-rich motifs did not accumulate cisplatin. Together
these data suggest that Ctr1 employs a different mechanism
for copper and cisplatin transport and the rapid conformational changes in Ctr1 observed during copper translocation
are not coupled with cisplatin uptake. The N-terminal Metrich motifs seem to play a significant role for Ctr1-mediated
cisplatin uptake. It is possible that binding of cisplatin to the
N terminus of Ctr1 followed by subsequent internalization
could be a mechanism for cisplatin uptake. The competition
between copper and cisplatin in their uptake (60) may be due
to internalization of Ctr1 by either copper and/or cisplatin,
which would reduce the availability of Ctr1 at the cell surface
thus reducing the uptake of either copper or cisplatin. However, copper- and cisplatin-induced internalization of Ctr1
(60, 74, 75) has been challenged by contrasting results indicating no effect of cisplatin on steady-state location of Ctr1 (58,
59, 67). Further elucidation of the mechanism of action and
regulation of Ctr1 would lead to a better understanding of
how Ctr1 can transport the essential mineral copper and the
anticancer drug cisplatin and whether abnormal Ctr1 function and regulation is linked to the development of cisplatin
resistance in cancer patients.
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